OBJECTIVES:
Primary
* Compare the survival of patients over 60 with glioblastoma multiforme treated with standard radiotherapy vs hypofractionated radiotherapy vs chemotherapy.
Secondary
* Compare the quality of life (QLQ-C30) of these patients.
* Compare the safety, tolerance, and toxicity of these regimens.
* Assess the pharmacoeconomic cost of these regimens.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.
* Arm I: Patients undergo standard radiotherapy 5 days a week for 6 weeks.
* Arm II: Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
* Arm III: Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.